Scribd Logo
Upload

Welcome to Scribd!

  • Patternox - One Pager

    Uploaded by

    Sandy Berger
    8 views1 page
    PatternOx was founded by Drs. Ofir Aharon, Barry Galitzer, Kleiner Yehuda, and Lopchinsky Richard to develop the PatScope imager to detect lesion distortions that may increase the risk of skin cancer. The PatScope uses innovative imaging to reveal subsurface distortions of lesions, boundaries, and non-pigmental changes in lesions that are difficult to detect otherwise. A clinical trial of the PatScope on 440 lesions showed it could detect these changes earlier than traditional imaging methods. PatternOx has developed prototypes, received regulatory approval, and is seeking $1-2 million in funding for commercialization and additional clinical trials.

    Original Description:

    Patternox

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    PatternOx was founded by Drs. Ofir Aharon, Barry Galitzer, Kleiner Yehuda, and Lopchinsky Richard to develop the PatScope imager to detect lesion distortions that may increase the risk of skin cancer. The PatScope uses innovative imaging to reveal subsurface distortions of lesions, boundaries, and non-pigmental changes in lesions that are difficult to detect otherwise. A clinical trial of the PatScope on 440 lesions showed it could detect these changes earlier than traditional imaging methods. PatternOx has developed prototypes, received regulatory approval, and is seeking $1-2 million in funding for commercialization and additional clinical trials.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    8 views1 page

    Patternox - One Pager

    Uploaded by

    Sandy Berger
    PatternOx was founded by Drs. Ofir Aharon, Barry Galitzer, Kleiner Yehuda, and Lopchinsky Richard to develop the PatScope imager to detect lesion distortions that may increase the risk of skin cancer. The PatScope uses innovative imaging to reveal subsurface distortions of lesions, boundaries, and non-pigmental changes in lesions that are difficult to detect otherwise. A clinical trial of the PatScope on 440 lesions showed it could detect these changes earlier than traditional imaging methods. PatternOx has developed prototypes, received regulatory approval, and is seeking $1-2 million in funding for commercialization and additional clinical trials.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    PATTERNOX LTD

    Founded by:
    Ofir Aharon, Ph.D.
    Barry Galitzer, Ph.D. MD.
    Innovate Imaging and detection Kleiner Yehuda, Ph.D.
    Lopchinsky Richard, Ph.D., M.D

    Problem Solution Accomplished to date


    Detection of lesion distortions that PatScope imager to reveal Lesion
    2024
    may increase the risk of cosmetic Distortions. ✓ BETA prototypes/MVP.
    concerns and skin cancer. ✓ Regulatory Pathway.
    ✓ Clinical Trial with 440 lesions and over
    • Innovative imager of lesion distortions
    • Color change or itching appear at a late 13,170 measurements at the
    including boundaries. For skin cancer
    stage. Late diagnosis leads to higher SKINCENTER, FL, USA.
    deep under and at an early stage.
    mortality rate. ✓ A new AI platform in Dev.
    • Lesions with the same color might have
    • Transparent boundary has no role. ✓ LOI's from distributors.
    different underneath distortion. PatScope
    • No method to prioritize the removal of ✓ Patent at the National Stage.
    is a tool to monitor distortions and non-
    multiple lesions. ✓ 2023 We've been chosen by the Israel
    pigmental deterioration.
    • The more Atypical moles, the higher the Innovation Authority (IIA)to
    risk of skin cancer. participate in the Israel-Singapore
    delegation .
    Clinical trial at the Needs of fund
    SkinCenter, USA $1M: Commercialization
    $2M: Class-I/II, FDA / CE
    Dermascope PatScope
    $2M: Sales and Marketing

    vs.
    Contact: Dr. Ofir Aharon, Tel: +972-526164669,
    ofir@patternox.com, www.patternox.com

    You might also like